<DOC>
	<DOCNO>NCT01265511</DOCNO>
	<brief_summary>This study examine effectiveness 28 day triple combination therapy include SCY-635 peginterferon alfa 2a ribavirin reduce serum HCV RNA level . An additional 20 week treatment currently approve standard care offer participant . The Week 24 visit last on-study visit . After Week 24 visit , subject undetectable HCV RNA give option continue treatment standard care additional 24 week ( Week 48 ) care Principal Investigator .</brief_summary>
	<brief_title>Study SCY-635 , Pegasys Copegus Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Quantifiable serum level HCVspecific RNA excess 100,000 IU/mL Chronic HCV status HCV genotype 1 infection IL28B genotype C/T T/T Liver biopsy result within 3 year prior screen indicate absence cirrhosis *If previous biopsy available , biopsy must perform screening period qualify randomization Body mass index ( BMI ) 18 38 kg/m2 Laboratory variable within acceptable range : ALT/AST &lt; 3 × ULN ; HgB &gt; 12g/dL female , &gt; 13 g/dL male ; total WBC count &gt; 3000/mm3 ANC &gt; 1500/mm3 ; platelet &gt; 100,000/mm3 ; prothrombin time ( INR ) ≤ 1.2 × ULN ; serum albumin ≥ 3.4 g/dL ; total bilirubin WNL ; serum creatinine WNL ; serum creatinine &gt; ULN , calculate creatinine clearance must &gt; 100 mL/min ( CockcroftGault formula ) subject eligible Subjects childbearing potential ( i.e. , surgically sterile postmenopausal ) must agree use 2 form contraception Screening 24 week completion treatment RBV Negative urine test amphetamine cocaine Screening . If female , subject negative pregnancy test Screening study Day 1 History clinically significant gastrointestinal , renal , hepatic , neurologic , hematologic , endocrine , oncologic , pulmonary , immunologic , psychiatric , cardiovascular disease Females pregnant breastfeeding Males partner pregnant plan become pregnant HCV genotype genotype 1 IL28B genotype C/C Seropositive HIV1 HIV2 hepatitis B virus ( HBV ) surface antigen ( HBsAg ) Use investigational agent within 3 month prior dose Received prior FDAapproved investigational drug drug regimen treatment hepatitis C Evidence cirrhosis previous liver biopsy Evidence decompensated liver disease Recipient organ transplant Evidence hepatocellular carcinoma Evidence ongoing alcohol substance abuse Poorlycontrolled diabetes mellitus Congestive heart failure unstable cardiopulmonary condition , renal disease , hemoglobinopathy ( sickle cell anemia thalassemia History seizure disorder History severe psychiatric illness , include severe depression , history suicidal ideation , suicidal attempt , related hospitalization , bipolar disorder , psychosis require medication Concurrent medical condition laboratory abnormality would constitute contraindication interferon use History unstable thyroid disease would preclude administration interferonbased therapy Medical condition require use systemic corticosteroid Received warfarin anticoagulant 21 day immediately prior Screening , expect require warfarin anticoagulant study . One additional know primary secondary cause liver disease , hepatitis C Any concurrent medical condition likely preclude compliance schedule evaluation , likely confound efficacy safety observation 12lead ECG show follow : Corrected QTc interval ≥ 450 msec ( Bazett 's correction ) ; QRS &gt; 120 msec ; Clinically significant abnormality ; Severe retinopathy significant ophthalmological disorder Use herbal supplement within 28 day prior dose . The use CYP3A inducer inhibitor least 2 week prior initiation treatment Week 6</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>SCY-635</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Interferon</keyword>
</DOC>